Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

Trial Profile

Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Dapagliflozin (Primary) ; Rifampicin (Primary)
  • Indications Tuberculosis; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 22 Mar 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 06 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top